Can aspirin or diabetes drugs tame fatty liver? new study reveals results
NCT ID NCT07338331
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looked at whether aspirin or a diabetes drug called an SGLT2 inhibitor (like dapagliflozin) can improve liver health in people with type 2 diabetes and non-alcoholic fatty liver disease. Researchers measured liver enzymes, cholesterol, and liver stiffness (using FibroScan) in 80 adults over 6 months. The goal was to see which treatment better controls liver damage and metabolic symptoms.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DIABETE TYPE 2 are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Faculty of Pharmacy
Banī Suwayf, Beni Suweif Governorate, 0000, Egypt
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Could meal kits and text messages help curb diabetes in Food-Insecure communities?
- Could exercise reshape gut bacteria in fatty liver disease?
- Walking downhill may boost heart health and strength in type 2 diabetes
- Could a simple supplement soothe diabetic nerve damage?
- Can family coaching cut diabetes risk? pilot study targets high-risk communities
- Could a probiotic supplement help reverse fatty liver?